A Phase 2 interventional study of YJ001 spray simulator and YJ001 Spray 240 mg/day in Diabetic Peripheral Neuropathic Pain (DPNP), sponsored by Zhejiang Yuejia Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Zhejiang Yuejia Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Neuralgia with a site in China — 16 open to participants now, 16 under way, 1 of them phase 3. Neuralgia · China.
Among the 40 studies in Neuralgia with a site in China, this one is the 11th largest by enrollment of the 30 interventional ones that give a count, is one of 8 that started in 2024, is one of 9 in phase 2, and was the 39th registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →16 of the 40 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18+
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 6 · Phase 4 2
First in 2006; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 52 across 832 interventional studies indexed under Neuralgia.
Median enrollment 158 across the 30 interventional studies, 300 across the 10 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 40 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Zhejiang Yuejia Pharmaceuticals Co., Ltd. as lead sponsor.
Zhejiang Yuejia Pharmaceuticals Co., Ltd. has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
4 of the studies in Neuralgia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06766916Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCrisugabalin for Radiotherapy-Related Neuropathic Pain | 2026-11-30 |
| NCT06596681Beijing Tiantan HospitalA Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain | 2026-12-31 |
| NCT07148388Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAccelerated Intermittent Theta Burst Stimulation (AiTBS)on Neuropathic Pain | 2027-09-01 |
| NCT07699770Tang-Du HospitalCrisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Neuralgia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if YJ001 Spray can treat diabetic patients with Diabetic Peripheral Neuropathic Pain(DPNP). The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: YJ001 spray simulator
Drug: YJ001 Spray 240 mg/day
Drug: YJ001 Spray 480 mg/day
Drug: YJ001 Spray 960 mg/day
YJ001 spray 0mg/ml,apply spray to both feet 0mg each time,twice daily, with six sprays per foot.
YJ001 spray 50mg/ml,apply spray to both feet 120mg each time,twice daily, with six sprays per foot.
YJ001 spray 100mg/ml,apply spray to both feet 240mg each time,twice daily, with six sprays per foot.
YJ001 spray 200mg/ml,apply spray to both feet 480mg each time,twice daily, with six sprays per foot
Change from baseline in weekly average Numeric Rating Scale (NRS) pain score at Week 12 after treatment.
Numeric Rating Scale (NRS). This scale ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain. Higher scores indicate worse pain severity
Time frame: baseline and week 12
Change from baseline in weekly average NRS pain scores during Week 1-11 after treatment and the follow-up period.
Numeric Rating Scale (NRS). This scale ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain. Higher scores indicate worse pain severity.
Time frame: baseline and weekly during Weeks 1-11
Change from baseline in weekly average NRS pain scores measured 6 hours after morning dosing during Weeks 1-12 after treatment.
Numeric Rating Scale (NRS). This scale ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain. Higher scores indicate worse pain severity.
Time frame: baseline and 6 hours after morning dosing during Weeks 1-12
Change from baseline in weekly average NRS pain scores before morning dosing during Week 1-12 after treatment.
Numeric Rating Scale (NRS). This scale ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain. Higher scores indicate worse pain severity.
Time frame: baseline,before morning dosing during Week 1-12
Change from baseline in weekly average NRS pain scores before evening dosing during Week 1-12 after treatment.
Numeric Rating Scale (NRS). This scale ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain. Higher scores indicate worse pain severity.
Time frame: baseline,before evening dosing during Week 1-12
Weekly responder rates (≥30 % and ≥50 % reduction) during Week 1-12 after treatment.
Responder is defined as ≥30% or ≥50% reduction in weekly average Numeric Rating Scale (NRS) pain score from baseline. NRS: 0-10, 0=no pain,10=worst imaginable pain, higher scores mean worse pain.
Time frame: Weekly during Week 1-12
Change from baseline in weekly average sleep interference scores during Week 1-12 after treatment and the follow-up period.
Weekly average sleep disturbance score. The scale ranges from 0 to 10. Higher scores indicate worse sleep disturbance.
Time frame: baseline,Week 1, 2, 4, 8, 12
Change from baseline in Visual Analogue Scale (VAS) pain scores derived from the Short-form McGill Pain Questionnaire(SF-MPQ) at Week 1, 2, 4, 8, 12 after treatment and the follow-up period.
Short-Form McGill Pain Questionnaire Verbal Analogue Scale (SF-MPQ-VAS). The scale ranges from 0 to 10. Higher scores indicate worse pain.
Time frame: baseline,Week 1, 2, 4, 8, 12
Change from baseline in Hospital Anxiety and Depression Scale (HADS) scores at Week 1, 2, 4, 8, 12 after treatment and the follow-up period.
Hospital Anxiety and Depression Scale (HADS). Total score ranges from 0 to 42. Higher scores indicate greater anxiety and depression symptoms.
Time frame: baseline,Week 1, 2, 4, 8, 12
Patient's Global Impression of Change (PGIC) at Week 12 after treatment.
Patient Global Impression of Change (PGIC). The scale ranges from 1 to 7. Lower scores indicate better improvement in pain.
Time frame: Week 12
Clinician's Global Impression of Change (CGIC) at Week 12 after treatment.
Clinician's Global Impression of Change (CGIC) is a 7-point clinician-rated scale. Scores range from 1 to 7: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. Lower scores indicate better clinical improvement.
Time frame: Week 12
Change from baseline in 36-Item Short-Form Health Survey (SF-36) scores at Week 12 after treatment.
Short Form-36 (SF-36) quality of life scale. Each domain score ranges from 0 to 100. Higher scores indicate better quality of life.
Time frame: baseline and Week 12
Change from baseline in superficial peroneal and sural nerve conduction velocity and action potential amplitude at Week 12 after treatment.
Nerve conduction velocity and compound nerve action potential amplitude of superficial peroneal nerve and sural nerve will be measured by nerve conduction studies. The change from baseline in these electrophysiological parameters will be assessed at Week 12 after treatment. Higher nerve conduction velocity and higher amplitude indicate better nerve function.
Time frame: baseline,Week 12
Change from baseline in serum tumour necrosis factor-α (TNF-α) level at Week 12 after treatment.
Serum tumour necrosis factor-α (TNF-α) concentration will be measured in blood samples. The change from baseline in serum TNF-α level will be evaluated at Week 12 after treatment. Lower TNF-α levels indicate reduced inflammatory status (better outcome).
Time frame: baseline,Week 12
The self-assessed time for significant pain relief by subjects after treatment (defined as pain NRS score before morning or evening dosing reduction ≥30 % from baseline).
This endpoint measures the self-assessed time to achieve significant pain relief by subjects. Significant pain relief is defined as a ≥30% reduction from baseline in the pre-morning or pre-evening dosing Numeric Rating Scale (NRS) pain score. The NRS ranges from 0 to 10, where 0 = no pain and 10 = worst imaginable pain. Higher scores indicate worse pain severity. The time to reach this pain relief threshold will be recorded throughout the trial.
Time frame: before morning or evening dosing throughout the entire clinical trial period
Changes in NRS pain scores before morning dosing, 1, 3, 6, 9 hours after morning dosing, and before evening dosing within 3 days after significant relief of self-reported pain by the subjects
This endpoint evaluates changes in subject-reported Numeric Rating Scale (NRS) pain scores. Assessments are collected at pre-morning dosing, 1, 3, 6, 9 hours after morning dosing, and pre-evening dosing within 3 days after subjects report significant pain relief. The NRS ranges from 0 to 10, where 0 = no pain and 10 = worst imaginable pain. Higher scores indicate worse pain severity.
Time frame: before morning dosing, 1, 3, 6, 9 hours after morning dosing, and before evening dosing within 3 days after significant relief of self-reported pain by the subjects
Number of participants with clinically significant abnormal laboratory values
Assessment of clinically significant abnormal laboratory values from hematology, serum biochemistry, coagulation and urinalysis tests. Laboratory panel includes hematology (RBC, Hb, WBC, NEU, PLT, NEU%, LYM%), serum biochemistry (AST, ALT, TBIL, GGT, ALP, DBIL, ALB, Scr, eGFR, HbA1c, FPG), coagulation (APTT, PT, TT, FIB, INR), urinalysis (PRO, GLU, LEU, UERY, urine pH).
Time frame: Pre-import period,baseline,Week 4, 8, 12
Number of participants with clinically significant abnormal 12/18-lead ECG findings
Assessment of clinically significant abnormal electrocardiogram (ECG) parameters from 12-lead or 18-lead ECG recordings, including heart rate, PR interval, QRS duration, QT interval, QTc interval, and morphological abnormalities.
Time frame: Pre-import period,baseline,Week 4, 8, 12
Number of participants with respiratory tract irritation related to spray administration
Incidence of respiratory tract irritation adverse events occurring during spray administration, assessed via clinical inquiry and physical examination at each study visit.
Time frame: Week 1,2,4, 8, 12
Any adverse events observed or reported throughout the study period will be documented promptly
Time frame: Pre-import period,baseline,Week 1,2, 4, 8, 12
Change from baseline in serum interleukin (IL-6) level at Week 12 after treatment.
Time frame: baseline ,Week 12
Change from baseline in serum interleukin IL-1β level at Week 12 after treatment.
Time frame: baseline,week 12
Ran from Jan 2024 to primary completion in Dec 2024, 11 months.
Of 34 industry-sponsored phase 2 interventional studies under Neuralgia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's 11 months is below that.
Counting every sponsor, half of 58 studies reached it within 22 months; a quarter within 11 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.